| Exudative age-related macular degeneration
Beovu vs Lucentis
Side-by-side clinical, coverage, and cost comparison for exudative age-related macular degeneration.Deep comparison between: Beovu vs Lucentis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLucentis has a higher rate of injection site reactions vs Beovu based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lucentis but not Beovu, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Beovu
Lucentis
At A Glance
Intravitreal injection
Every 8-12 weeks (maintenance)
VEGF-A inhibitor
Intravitreal injection
Monthly
VEGF-A antagonist
Indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Exudative age-related macular degeneration
- Macular retinal edema
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Myopic choroidal neovascularization
Dosing
Exudative age-related macular degeneration 6 mg (0.05 mL) by intravitreal injection monthly (every 25-31 days) for first 3 doses, followed by 6 mg every 8-12 weeks.
Macular edema due to diabetes mellitus 6 mg (0.05 mL) by intravitreal injection every 6 weeks (every 39-45 days) for first 5 doses, followed by 6 mg every 8-12 weeks.
Exudative age-related macular degeneration 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly; less frequent dosing with regular assessment may be considered after 3-4 initial monthly doses.
Macular retinal edema 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly.
Macular edema due to diabetes mellitus, Diabetic Retinopathy 0.3 mg (0.05 mL of 6 mg/mL) intravitreal injection once monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly for up to 3 months; retreat as needed.
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to brolucizumab or any excipient in BEOVU
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab or any excipient in LUCENTIS
Adverse Reactions
Most common (>=1%) Vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, eye pain, intraocular inflammation, intraocular pressure increased, retinal hemorrhage, vitreous detachment, conjunctivitis, retinal pigment epithelial tear, corneal abrasion, hypersensitivity, punctate keratitis, retinal tear, endophthalmitis, blindness, retinal artery occlusion, retinal detachment, conjunctival hyperemia, lacrimation increased, abnormal sensation in eye, detachment of retinal pigment epithelium, vitreous hemorrhage
Serious Endophthalmitis, retinal detachment, retinal vasculitis, retinal vascular occlusion, intraocular pressure increase, thromboembolic events, hypersensitivity
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, vitreous detachment, intraocular inflammation, cataract, foreign body sensation in eyes, eye irritation, lacrimation increased, nasopharyngitis, headache
Serious Endophthalmitis, retinal detachment, rhegmatogenous retinal detachment, iatrogenic traumatic cataract, thromboembolic events, fatal events in patients with DME and DR
Postmarketing Tear of retinal pigment epithelium in patients with neovascular AMD
Pharmacology
VEGF-A inhibitor; brolucizumab is a humanized monoclonal single-chain Fv (scFv) antibody fragment that binds the three major isoforms of VEGF-A (VEGF110, VEGF121, VEGF165), blocking VEGFR-1 and VEGFR-2 interaction to suppress endothelial cell proliferation, neovascularization, and vascular permeability.
Ranibizumab is a VEGF-A antagonist; a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Beovu
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Lucentis
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (0/12)
UnitedHealthcare
Beovu
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lucentis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Beovu
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lucentis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LucentisView full Lucentis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.